ATROVENT

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Malta, Mexico, Netherlands, New Zealand, Poland, Singapore, South Africa, Spain, Tunisia, UK.

Active ingredients

The drug ATROVENT contains one active pharmaceutical ingredient (API):

1	Ipratropium bromide anhydrous UNII J697UZ2A9J - IPRATROPIUM BROMIDE
	Ipratropium is a quaternary ammonium compound with anticholinergic (parasympatholytic) properties. Ipratropium appears to inhibit vagally mediated reflexes by antagonising the action of acetylcholine, the transmitter agent released from the vagus nerve. Anticholinergics prevent the increase in intracellular concentration of Ca++, which is caused by interaction of acetylcholine with the muscarinic receptor on bronchial smooth muscle. Ca++ release is mediated by the second messenger system consisting of IP3 (inositol triphosphate) and DAG (diacylglycerol).
	Read more about Ipratropium

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ATROVENT Nebuliser solution	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)
ATROVENT HFA Inhalation aerosol, metered	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R01AX03	Ipratropium bromide	R Respiratory system → R01 Nasal preparations → R01A Decongestants and other nasal preparations for topical use → R01AX Other nasal preparations
Discover more medicines within R01AX03
R03BB01	Ipratropium bromide	R Respiratory system → R03 Drugs for obstructive airway diseases → R03B Other drugs for obstructive airway diseases, inhalants → R03BB Anticholinergics
Discover more medicines within R03BB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	1542E, 4089F, 4090G, 8238N, 8671J
BR	Câmara de Regulação do Mercado de Medicamentos	504500501178319, 504500504177313
CA	Health Products and Food Branch	02247686
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	25.076-04-03, 29385-1-09-10
EE	Ravimiamet	1057711, 1105940, 1567470, 1874448
ES	Centro de información online de medicamentos de la AEMPS	54674, 61184, 61185, 61848
FI	Lääkealan turvallisuus- ja kehittämiskeskus	099486, 129817
FR	Base de données publique des médicaments	61267669, 65756091, 66698997, 66871253, 67838060, 69720897
GB	Medicines & Healthcare Products Regulatory Agency	180714, 201649, 299787, 299788, 299790, 299791, 32225, 32266, 375964, 73900
HK	Department of Health Drug Office	23564, 36372, 50402
HR	Agencija za lijekove i medicinske proizvode	HR-H-119167758, HR-H-535873913
IE	Health Products Regulatory Authority	14397, 67618, 71220
IL	מִשְׂרַד הַבְּרִיאוּת	4715
JP	医薬品医療機器総合機構	2259702G2021
LT	Valstybinė vaistų kontrolės tarnyba	1004213, 1084153
MT	Medicines Authority	MA211/01001, MA211/01002, PI1438/09101A, PI908/18601A
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	161M82, 189M97
NL	Z-Index G-Standaard	13804510, 13804529, 14691159
NL	Z-Index G-Standaard, PRK	29378, 38717, 73377
NZ	Medicines and Medical Devices Safety Authority	10628
PL	Rejestru Produktów Leczniczych	100008205, 100114137
SG	Health Sciences Authority	02815P, 12002P
TN	Direction de la Pharmacie et du Médicament	5213074
US	FDA, National Drug Code	0597-0087, 50090-0961
ZA	Health Products Regulatory Authority	37/10.2.1/0273, Z/10.2.1/48